BIOCRYST PHARMACEUTICALS, INC. Receivables, Net, Current
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Receivables, Net, Current of $1.00 million as of 2024-09-30, per its 10-Q filed 2024-11-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:ReceivablesNetCurrent · last filed 2024-11-05
- 2024-09-30: Receivables, Net, Current $1.00M.
- 2024-06-30: Receivables, Net, Current $2.12M.
- 2024-03-31: Receivables, Net, Current $3.58M.
- 2023-12-31: Receivables, Net, Current $2.30M.
| Period end | Receivables, Net, Current |
|---|---|
| 2024-09-30 | $1.00M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $2.12M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $3.58M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $2.30M 10-Q · filed 2024-11-05 |
| 2023-09-30 | $1.68M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $2.07M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.09M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $8.27M 10-K · filed 2024-02-27 |
| 2022-09-30 | $3.02M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $1.84M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $1.93M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.98M 10-K · filed 2023-02-27 |
| 2021-09-30 | $3.29M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $6.51M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $8.50M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $8.24M 10-K · filed 2022-02-28 |
| 2020-09-30 | $5.42M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $4.00M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $5.64M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $22.15M 10-K · filed 2021-03-01 |
| 2019-09-30 | $3.60M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $3.60M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $5.00M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $4.29M 10-K · filed 2020-03-13 |
| 2018-09-30 | $3.39M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $2.34M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $5.69M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $6.12M 10-K · filed 2019-03-14 |
| 2017-09-30 | $8.98M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $3.33M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $9.56M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $8.77M 10-K · filed 2018-03-12 |
| 2016-09-30 | $5.97M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $2.23M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $7.38M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $6.24M 10-K · filed 2017-02-27 |
| 2015-09-30 | $7.50M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $4.30M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $5.59M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $3.85M 10-K · filed 2016-02-26 |
| 2014-09-30 | $3.24M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $897.00K 10-Q · filed 2014-08-08 |
| 2014-03-31 | $3.28M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $2.12M 10-Q · filed 2014-11-07 |
| 2013-09-30 | $2.37M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $1.02M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $4.33M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $4.56M 10-K · filed 2014-03-10 |
| 2012-09-30 | $3.77M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $5.08M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $5.85M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $5.83M 10-K · filed 2013-03-11 |
| 2011-09-30 | $11.63M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $15.96M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $30.23M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |